Abeona Therapeutics Announces Upcoming Presentations

NEW YORK and CLEVELAND, May 08, 2018 -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical- stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced upcoming presentations during two conferences, both to take place May 16 - 19, 2018; the 21^st annual American Society of Gene and Cell Therapy 2018 conference being held in Chicago, IL, and the International Investigative Dermatology conference being held in Orlando, FL. 

American Society of Gene and Cell Therapy
https://www.asgct.org/

Oral Presentations:

Phase 1/2 Clinical Trial for Recessive Dystrophic Epidermolysis Bullosa Using EB-101 (COL7A1 Gene-Corrected Autologous Keratinocytes)
Presenter: Jean Yuh Tang, M.D., Ph.D., Stanford University
Thursday, May 17, 2018
Time: 8:20 AM Central Time

Update on Phase 1/2 Gene Transfer Clinical Trial of Systemic Gene Transfer of scAAV9.U1a.hSGSH for MPSIIIA (Sanfilippo Syndrome)
Presenter: Kevin Flanigan, M.D., Nationwide Children's Hospital
Friday, May 18, 2018
Time: 8:30 AM Central Time

A Phase 1/2 Clinical Trial of Systemic Gene Transfer of rAAV9.CMV.hNAGLU for MPS IIIB: Safety, Tolerability, and Preliminary Evidence of Biopotency
Presenter: Kevin Flanigan, M.D., Nationwide Children's Hospital
Friday, May 18, 2018
Time: 4:30 PM Central Time

Symposium and Forum:

Assessing Neurodevelopment in Neurodegenerative Disease: The Use and Interpretation of Cognitive Scales
Presenter: Maria Escolar, M.D., Children's Hospital of Pittsburgh of UPMC
Moderator: Barry Byrne, M.D., Ph.D., University of Florida
Thursday, May 17, 2018
Time: 7:00 AM Central Time

Tools and Technologies Forum
Co-Chair: S. Kaye Spratt, Ph.D., Abeona Therapeutics Inc.
Friday, May 18, 2018
Time: 5:45 PM – 7:45 PM Central Time

Poster Presentations:

Poster 547: Development of a Multi-Domain Responder Index for Clinical Trials with Multi-Domain Diseases
Presenter: Magdalena Tyrpien, Abeona Therapeutics Inc.
Thursday, May 17, 2018
Time: 5:15 PM Central Time

Poster 399: Identification of Novel AAV Capsids for Enhanced CNS Gene Transfer
Presenter: Daphne Chen, University of North Carolina, Chapel Hill
Thursday, May 17, 2018
Time: 5:15 PM Central Time

International Investigative Dermatology

https://iid2018.org/

Poster Presentation:

Poster 328: 50% Wound Healing Correlates with RDEB Patient Reported Outcomes in Pain, Itch, and Skin Durability
Friday, May 18, 2018
Time: 12:00 PM Eastern Time

About Abeona: Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for life- threatening rare genetic diseases. Abeona's lead programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV-NAGLU), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type B (MPS IIIB). Abeona is also developing ABO-201 (AAV-CLN3) gene therapy for CLN3 disease, ABO-202 (AAV-CLN1) for treatment of CLN1 disease, EB-201 for epidermolysis bullosa (EB), ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. In addition, Abeona is developing a proprietary vector platform, AIM™, for next generation product candidates. For more information, visit www.abeonatherapeutics.com.

Investor Contact:
Christine Silverstein
SVP, Investor Relations & Finance
Abeona Therapeutics Inc.
+1 (646) 813-4707
[email protected]

Media Contact:
Lynn Granito
Berry & Company Public Relations
+1 (212) 253-8881
[email protected]

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements are subject to numerous risks and uncertainties, including but not limited to continued interest in our rare disease portfolio, our ability to enroll patients in clinical trials, the impact of competition; the ability to develop our products and technologies; the ability to achieve or obtain necessary regulatory approvals and licenses; the impact of changes in the financial markets and global economic conditions; and other risks as may be detailed from time to time in the Company's Annual Reports on Form 10-K and other reports filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.